UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 内臓リーシュマニア症：治療visceral leishmaniasis treatment [show details]
…therapy. Agents with activity against visceral leishmaniasis (VL) include amphotericin B, pentavalent antimonial drugs, paromomycin (a parenteral aminoglycoside), and miltefosine (the first oral drug for treatment …
2. 皮膚リーシュマニア症：治療cutaneous leishmaniasis treatment [show details]
… overview of oral systemic therapy is discussed above. Azole drugs alter biosynthesis of ergosterol, thereby modifying the components of the Leishmania parasite membrane . The use of azoles is limited to specific …
3. 内臓リーシュマニア症：疫学と管理visceral leishmaniasis epidemiology and control [show details]
… seasonality, preferred blood meal sources, aggregation, and resting behavior . Leishmaniasis can also be transmitted via intravenous drug use, blood transfusion, organ transplantation, congenital infection, and …
4. HIV感染患者における発熱および発疹fever and rash in hiv infected patients [show details]
… includes pain/discomfort, induration, erythema, nodules/cysts, pruritus, and/or ecchymosis . Other anti-HIV agents, including integrase strand transfer inhibitors (eg, bictegravir, dolutegravir, elvitegravir … Cutaneous manifestations may also be present in the setting of leishmaniasis. High Leishmania-HIV coinfection rates have been reported in Brazil,…
5. 資源の限られた地域で生じるHIV感染症への抗レトロウイルス薬の使用と効果use and impact of antiretroviral therapy for hiv infection in resource limited settings [show details]
… There are multiple pharmacologic interactions between ART and anti-tuberculosis medications with additive toxicities .… patients with higher HBV DNA viral loads, but has not been treatment limiting . The incidence of leishmania/HIV coinfection is increasing worldwide. Regions that are considered endemic are expanding through …